Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT). This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract ...

A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors. This is an ASCO Meeting Abstract from the ...